Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor to raise approximately $2.9 million through a registered direct offering and a concurrent private placement of warrants.

The company is selling 3,625,000 shares of common stock at $0.795 per share in the registered direct offering. The concurrent private placement includes warrants to purchase 3,625,000 shares of common stock at an exercise price of $0.84 per share, priced at $0.005 per warrant.

The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions. Dyadic said it intends to use the net proceeds for general corporate purposes and working capital.

Aegis Capital Corp. is acting as exclusive placement agent for the offerings.

The registered direct offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission and declared effective on Aug. 25, 2023. The warrants issued in the private placement have not been registered under the Securities Act of 1933 and were offered only to accredited investors. Dyadic has agreed to file one or more registration statements with the SEC covering the resale of the shares issuable upon exercise of the warrants.